ATM and ATR assay and IC 50 determination
HA-ATM and FLAG-ATR (HA-labeled ATM, and FLAG-labeled ATR) were each transiently expressed in HEK293 cells (293FT cells, Invitrogen Cat: R700-07) using Lipofectamine as transfection reagent. Cells were harvested 6 days post transfection and spun down to separate cells from media. Cells were then lysed using a lysis buffer (50 mM Tris buffer, (Tris(hydroxylmethyl)-aminomethane, pH 7.5), 100 mM NaCl, 50 mM βGOP, 10% Glycerol, 0.5% Tween 20, 1 mM EDTA, 25 mM sodium fluoride (NaF), 20 nM microcystine, 2 mM phenylmethylsulfonylfluoride (PMSF) and protease inhibitor cocktail) followed by sonication 3 times and a final spin at 20,000 rpm for 30 minutes to generate a clear lysate. To perform the immunoprecipitation, enzymes were captured on Protein G Sepharose from GE Healthcare (Cat. No. 17-0618-01) using specific antibodies to the HA or FLAG tags. Beads plus enzymes were then washed 3 times with lysis buffer and spun down at 1000 rpm for 1 minute. Beads plus enzymes were resuspended in lysis buffer and kept at 4°C until assay. Assays for ATM and ATR were conducted in a 33 P radioactive assay format. Assay buffer contained the following reagents: 1 mg/mL GST-p53 (glutathione S-transferase-p53 fusion protein) substrate (expressed in-house), 20 μg/mL calf thymus DNA activator (Sigma), 100 μg/mL BSA, 200 μM EGTA (ethylene glycol tetraacetic acid), 100 μM EDTA, and 1 mM DTT. Reactions were run in a 100-μL assay volume. The ATP concentration used for all 3 assays was 100 μM with 3 μCi of 33 P-labeled ATP per well (Perkin-Elmer Catalog No. NEG602H001MC). Reaction times were 3.5 hours for ATM and 4 hours for ATR. Reactions were stopped with 100 μL of 3% phosphoric acid. Samples were then transferred to a filter plate and washed with 0.75% phosphoric acid using a vacuum manifold. After allowing wells to dry for 15 minutes, 50 μL of scintillation fluid were added to each well, and the plate was read using a Topcount reader. Enzyme inhibition by CC-115 was tested from 2 separate dispenses in triplicate at 2 concentrations (3 and 30 μM). The total radioactivity incorporated in the presence of CC-115 was compared with the radioactivity incorporated in the corresponding no inhibitor control to determine percent inhibition. An IC 50 value was then estimated.
Cellular NHEJ assay
The experimental design is illustrated in Supplementary Figure 4 . Cal-51 breast cancer cells were separately transfected with pEGFP plasmid (6085-1, Clontech, Mountain View, CA) digested with either EcoRI (to measure NHEJ) or StuI (to measure transfection efficiency) using a Amaxa cell line nuclearfector kit V (CCA-1003, Lonza). Immediately after the transfection, the cells were treated with DMSO or compounds at indicated concentrations for 24 hours and GFP-positive cells were counted under a fluorescent microscope. NHEJ activity was calculated by the number of GFP-positive cells in cells transfected with pEGFP-EcoRI divided by that in cells transfected with pEGFP-StuI, multiplied by 100. To quantitatively determine the potency of CC-115 and other compounds in inhibition of NHEJ activity in multiple cell lines, a higher throughput NHEJ assay was developed. Different cell lines were transfected using the procedure described above and subsequently seeded into 384-well plates at optimized density for individual cell lines. Cells were then treated with compounds at increasing concentrations. GFP+ cells were imaged and quantitated using the IncuCyte (Essen Bioscience, Ann Arbor, MI). NHEJ activity was then normalized to the DMSO control and fitted to the Sigmoidal DoseResponse Model (IDBS XLFit Model 205; London, UK) to determine the activity of each compound. Results were expressed as a IC 50 value, which is the compound concentration required to inhibit 50% of GFP-positive cells during the 24 hours of treatment compared to the DMSO control. The IC 50 value was calculated using the following equation: y = (A+ ((B-A) / (1 + ((C/x)^D)))) where A = Y Min, B = Y Max , C = EC 50 , D = Hill Slope, y = Relative NHEJ activity, and the IC 50 is the concentration of the compound when y = 50% of DMSO control.
Immunofluorescence
DLD1 or LoVo human colorectal cancer cell lines cultured on coverslips were extracted with Cytoskeleton (CSK) buffer (0.5% Triton-X100, 10 mM Hepes, pH 7.4, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 , 50 mM NaF, and 0.1 mM NaVO 3 ) on ice for 5 minutes to remove cytosolic and nucleosolic proteins but retain the chromatin-bound proteins, fixed with 4% phosphate buffered paraformaldehyde solution for 10 minutes, neutralized with 0.1 M glycine for 5 minutes, and incubated in blocking buffer (0.4% Triton X-100, 2% fetus bovine serum in PBS) for 20 minutes at room temperature. The cells were incubated with mouse anti-Rad51 antibody, washed with washing buffer (0.2% Triton X-100 and 0.2% BSA in PBS), and then incubated with Alexa Fluor594-conjugated goat anti-mouse secondary antibody (invitrogen, Carlsbad, CA) at room temperature for 1 hour. After washing, the cells were mounted in ProLong Antifade mounting solution (invitrogen, Carlsbad, CA) with 4′,6-diamidino-2-phenylindole (DAPI) and sealed. The slides were imaged and photographed using a fluorescent microscope. All images were processed using Adobe Photoshop for presentation. To monitor inhibition of HR by CC-115, at least 600 nuclei from each slide were counted and HR efficiency was calculated by number of the nuclei containing more than 10 foci (HR positive) per number of the total nuclei.
